Skip to Main Content

Frustrated by White House efforts to tackle rising drug prices, a pair of U.S. lawmakers is urging the Trump administration to more squarely focus on drug makers — by backing legislation requiring them to justify their pricing and provide a breakdown of expenses before raising prices on some medicines.

In a letter to be sent on Monday to President Trump, Sens. Tammy Baldwin (D-Wis.) and John McCain (R-Ariz.) urge him to “make good on your promise” to fix a problem that is vexing an increasing number of Americans by backing the Fair Accountability and Innovative Research Drug Pricing Act, which they introduced last May. An identical bill was also introduced in the House, but both have languished.


The bill would require drug makers to notify the Department of Health and Human Services and submit a report 30 days before they increase the price of certain drugs costing at least $100 by more than 10 percent in one year, or 25 percent over three years. The reports would also need to cite manufacturing, R&D, and marketing costs, as well as net profits associated with the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Senators can scream and holler as much as they can about high drug prices. Irony is they are in Pharma pockets. Peggy Noonan in WSJ column [] very rightly says “Both parties are corrupt and look out only for themselves…” have no interest when they take funds to preserve their jobs. There is a saying “do not cut the hand that feeds you”.
    So legislators can hoot and holler but nothing will happen. People eventually will die whether they can afford drugs or not. It is just a question of time.

Comments are closed.